A Welcome Letter

Dear Colleagues and Friends:

Thank you for your interest in ELISA/ACT Biotechnologies LLC (EAB), a leading clinical laboratory specializing in immunology testing.

For more than 30 years, we have developed integrative, evidenced-based, first line comprehensive care clinical protocols. Our unique Lymphocyte Response Assay by ELISA/ACT™ (LRA) tests and treatment plans address the causes (not the symptoms) of patients’ chronic autoimmune and immune dysfunction conditions, often linked to their delayed allergies. Our validated lab offers you these unique benefits:

  • Successful randomized controlled studies,
  • Case-controlled studies reported quarterly,
  • More than 30 years of proven clinical success,
  • Exceptional service to top clinicians everywhere,
  • CLIA certification

For over 40 years, as a biochemist, internist, clinical pathologist, and immunologist interested in the mechanisms of health, my focus has been on the role of delayed allergies (hypersensitivities) as the hidden, underlying, yet fundamental causes of autoimmune and immune dysfunction chronic illness. I believe that specific, clinically predictive technology and validated protocols like our LRA tests improve patient care, patient satisfaction, and patient outcomes, while reducing total cost of care.

In the beginning, I worked with cell response technologies, specifically advanced lymphocyte response assays (LRAs), to determine the best way to obtain an accurate “fingerprint of the immune system memory.” This detailed “map” would analyze a person’s delayed hypersensitivity responses to items such as foods and chemicals that may be burdening their immune system and causing unexplainable symptoms like muscle aches, joint pain, migraines, skin rashes, bloating, and more.

We have found that addressing the causes of these chronic, treatment-resistant conditions is much more effective than just suppressing symptoms. After many years of research and clinical outcome studies to support the reliability and validity of this testing method, the end result was the unique LRA tests and treatment plan, which tests for a patient’s delayed hypersensitivity reactions to 500 plus foods and preservatives, environmental chemicals and medications, molds and exotic items.

Using our patented technology and by following our comprehensive care treatment plan, patients can repair their immune system and improve their quality of life. After performing over 20 million lymphocyte response assays, it has been inspiring to see such sustained positive results from over 50,000 chronically ill people who have been documented to have successfully followed our program.

We share your commitment to reducing people’s suffering and improving their productivity and quality of life. We are grateful for the opportunity to serve healthcare professionals and their patients around the world.

Russ Jaffe
Warm Russ Photo

Russell M. Jaffe, MD, Ph.D., CCN, NACB
Founder, Lab Director, and CEO